Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom

Journal of Psychopharmacology

Volumn 21, Issue 6, 2007, Pages 588-596

  McKendrick, J ^a   Cerri, K H ^a   Lloyd, A ^b   D'Ausilio, A ^b   Dando, S ^a   Chinn, C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Fourth Hurdle Consulting Ltd   (United Kingdom)

Author keywords

Bipolar disorder; Cost effectiveness; Olanzapine

Indexed keywords

FLUOXETINE; LITHIUM; OLANZAPINE; VALPROATE SEMISODIUM;

ANALYTICAL PARAMETERS; ARTICLE; BIPOLAR DISORDER; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITAL PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MOOD DISORDER; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HOSPITAL COSTS; HUMANS; LITHIUM COMPOUNDS; MARKOV CHAINS; MODELS, ECONOMIC; RECURRENCE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; STOCHASTIC PROCESSES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34748844514     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106068395     Document Type: Article

References (21)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders. 4 th edn. Washington, DC
2. Begley C E., Annegers J F., Swann A C., Lewis C., Coan S., Schnapp W B., Bryant-Comstock L. (2001) The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. PharmacoEconomics 19 (5 Pt 1). 483 - 495
3. British National Formulary (BNF) (2003) BMA & RPSGB, London
4. Das Gupta R, Guest J.F. (2002) Annual cost of bipolar disorder to UK society. Br J Psychiatry 180: 227 - 233
5. Dean B.B., Gerner D., Gerner R.H. (2004) A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 20: 139 - 154
6. Eli Lilly (2004) Zyprexa® summary of main product characteristics. Available at: http://emc.medicines.org.uk /. Eli Lilly and Company Limited, Basingstoke, UK
7. Finnern H W., Lothgren M., Ganghi G. (2002) Direct medical costs associated with bipolar disorder in the UK. Poster presented at Bipolar Disorders. Third European Stanley Foundation Conference on Bipolar Disorder 4: 122
8. Goodwin G M. (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17: 149 - 173
9. Keck P E. Jr, Nabulsi A A., Taylor J L., Henke C J., Chmiel J J., Stanton S P., Bennett J A. (1996) A pharmacoeconomic model of divalproex vs lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 57: 213 - 222
10. Maj M., Pirozzi R., Formicola A.M., Bartoli L., Bucci P. (2000) Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: preliminary data. J Affect Disord 57: 95 - 98
11. Monthly Index of Medical Specialities (MIMS) (August 2004)
12. Murray C.J., Lopez A.D. (1997) Global mortality, dizability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436 - 1442
13. National Institute for Clinical Excellence (2003) Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder. Technology Appraizal 66. National Institute for Clinical Excellence, London, UK
14. National Institute of Mental Health (2001) Bipolar Disorder. National Institute of Mental Health, Alexandria, VA
15. Netten A., Curtis L. (2003) Unit Costs of Health and Social Care. Personal and Social Services Research Unit (PSSRU). Available at: www.pssru.ac.uk
16. Tohen M., Bowden C., Calabrese J. Chou J., Jacobs T., Baker R., Williamson D., Evans A. (2003 a) Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomised double blind placebo-controlled 12-month clinical trial. European Neuropsychopharmacology 13 (suppl. 4). S213
17. Tohen M., Ketter T.A., Zarate C.A., Suppes T., Frye M., Altshuler L., Zajecka J., Schuh L.M., Risser R.C., Brown E., Baker RW (2003 b) Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 160: 1263 - 1271
18. Tohen M., Chengappa K N R, Suppes T., Baker R.W., Zarate C.A., Bowden C.L., Sachs G.S., Kupfer D.J., Ghaemi S.N., Feldman P.D., Risser R.C., Evans A.R., Calabrese J.R. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. B J Psych 184: 337 - 345
19. Tohen M., Greil W., Calabrese J R., Sachs G S., Yatham L N., Müller Oerlinghausen B., Koukopoulos A., Cassano G B., Grunze H., Licht R W., Dell'Osso L., Evans A R., Risser R., Baker R W., Crane H., Dossenbach M R., Bowden C L. (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind controlled clinical trial. Am J Psychiatry 162 (7). 1281 - 1290.
20. UK Psychiatric Pharmacy Group support document and information on lithium and valproate monitoring requirements (valproate: www.ukppg.co.uk/02-05- valproate-monitoring.rtf,lithiumwww.ukppg.co.uk/02-05-lithium-monitoring.rtf)
21. World Health Organization (2002). Mental Health: New Understanding, New Hope. The World Health Report 2001